Emerging drugs for high-grade osteosarcoma

Claudia Maria Hattinger, Michela Pasello, Stefano Ferrari, Piero Picci, Massimo Serra

Research output: Contribution to journalArticle

Abstract

Importance of the field: Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. This review focuses on the most promising therapeutic markers and drugs which may potentially be considered for innovative high-grade OS treatments. Areas covered in this review: The list of drugs and compounds reviewed has been generated by taking into account those which target markers of potential clinical interest for high-grade OS and have been included in Phase I, II or III clinical trials. The literature search covers the last 40 years, starting from the first OS chemotherapy reports of the early 1970s. Particular relevance was given to reports and reviews on new targeted therapies of possible clinical usefulness for high-grade OS. What the reader will gain: This review gives an updated overview of novel therapeutic approaches which have been or are going to be evaluated in Phase I/II/III clinical studies for high-grade OS. Take home message: On the basis of the information that has emerged so far, it can be predicted that in the next 5-10 years, new agents to be included in innovative treatment strategies for selected subgroups of high-grade OS patients may become available.

Original languageEnglish
Pages (from-to)615-634
Number of pages20
JournalExpert Opinion on Emerging Drugs
Volume15
Issue number4
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Osteosarcoma
Pharmaceutical Preparations
Therapeutics
Phase III Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Biomarkers
Bone and Bones
Drug Therapy
Neoplasms

Keywords

  • drug resistance
  • osteosarcoma
  • tailored therapy
  • target-specific drugs
  • therapeutic markers

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging drugs for high-grade osteosarcoma. / Hattinger, Claudia Maria; Pasello, Michela; Ferrari, Stefano; Picci, Piero; Serra, Massimo.

In: Expert Opinion on Emerging Drugs, Vol. 15, No. 4, 12.2010, p. 615-634.

Research output: Contribution to journalArticle

@article{5ac2e518cdf747e6a96d49985fac0ef1,
title = "Emerging drugs for high-grade osteosarcoma",
abstract = "Importance of the field: Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. This review focuses on the most promising therapeutic markers and drugs which may potentially be considered for innovative high-grade OS treatments. Areas covered in this review: The list of drugs and compounds reviewed has been generated by taking into account those which target markers of potential clinical interest for high-grade OS and have been included in Phase I, II or III clinical trials. The literature search covers the last 40 years, starting from the first OS chemotherapy reports of the early 1970s. Particular relevance was given to reports and reviews on new targeted therapies of possible clinical usefulness for high-grade OS. What the reader will gain: This review gives an updated overview of novel therapeutic approaches which have been or are going to be evaluated in Phase I/II/III clinical studies for high-grade OS. Take home message: On the basis of the information that has emerged so far, it can be predicted that in the next 5-10 years, new agents to be included in innovative treatment strategies for selected subgroups of high-grade OS patients may become available.",
keywords = "drug resistance, osteosarcoma, tailored therapy, target-specific drugs, therapeutic markers",
author = "Hattinger, {Claudia Maria} and Michela Pasello and Stefano Ferrari and Piero Picci and Massimo Serra",
year = "2010",
month = "12",
doi = "10.1517/14728214.2010.505603",
language = "English",
volume = "15",
pages = "615--634",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Emerging drugs for high-grade osteosarcoma

AU - Hattinger, Claudia Maria

AU - Pasello, Michela

AU - Ferrari, Stefano

AU - Picci, Piero

AU - Serra, Massimo

PY - 2010/12

Y1 - 2010/12

N2 - Importance of the field: Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. This review focuses on the most promising therapeutic markers and drugs which may potentially be considered for innovative high-grade OS treatments. Areas covered in this review: The list of drugs and compounds reviewed has been generated by taking into account those which target markers of potential clinical interest for high-grade OS and have been included in Phase I, II or III clinical trials. The literature search covers the last 40 years, starting from the first OS chemotherapy reports of the early 1970s. Particular relevance was given to reports and reviews on new targeted therapies of possible clinical usefulness for high-grade OS. What the reader will gain: This review gives an updated overview of novel therapeutic approaches which have been or are going to be evaluated in Phase I/II/III clinical studies for high-grade OS. Take home message: On the basis of the information that has emerged so far, it can be predicted that in the next 5-10 years, new agents to be included in innovative treatment strategies for selected subgroups of high-grade OS patients may become available.

AB - Importance of the field: Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. This review focuses on the most promising therapeutic markers and drugs which may potentially be considered for innovative high-grade OS treatments. Areas covered in this review: The list of drugs and compounds reviewed has been generated by taking into account those which target markers of potential clinical interest for high-grade OS and have been included in Phase I, II or III clinical trials. The literature search covers the last 40 years, starting from the first OS chemotherapy reports of the early 1970s. Particular relevance was given to reports and reviews on new targeted therapies of possible clinical usefulness for high-grade OS. What the reader will gain: This review gives an updated overview of novel therapeutic approaches which have been or are going to be evaluated in Phase I/II/III clinical studies for high-grade OS. Take home message: On the basis of the information that has emerged so far, it can be predicted that in the next 5-10 years, new agents to be included in innovative treatment strategies for selected subgroups of high-grade OS patients may become available.

KW - drug resistance

KW - osteosarcoma

KW - tailored therapy

KW - target-specific drugs

KW - therapeutic markers

UR - http://www.scopus.com/inward/record.url?scp=78649460883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649460883&partnerID=8YFLogxK

U2 - 10.1517/14728214.2010.505603

DO - 10.1517/14728214.2010.505603

M3 - Article

C2 - 20690888

AN - SCOPUS:78649460883

VL - 15

SP - 615

EP - 634

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 4

ER -